|Articles|October 1, 2021

Determining Weight Gain on ART Therapy

Investigators wanted to understand this phenomenon with a group of antiretroviral (ART) naïve people with HIV (PWH).

Initiation of ART therapy is associated with weight gain, and with it come concerns related to this side effect.

In a study presented virtually at IDWeek, investigators wanted to study the factors associated with massive weight gain as well as to assess if early weight gain could help predict massive weight gain at two years.

This study was retrospective looking at PWH initiating ART therapy from January 2005 through March 2019, and who follow-up interactions 21 to 27 months without ART changes, and were suppressed (HIV-RNA < 200 cps/ml) during that time.

The investigators defined massive weight gain as the top 20% of weight gainers at two years measured by percent gained compared to baseline. “Using bivariate and multivariate logistic regression (including factors in bivariate analysis with p< 0.20), we assessed the association of demographics, ART regimen, baseline CD4 count, HIV viral load, and body mass index (BMI) with weight gain at 2 years,” the investigators wrote. “We also assessed early weight gain (between 4 and 12 wks) and its association with massive weight gain at two years.”

Of 266 PWH included in the study, 36 years was the median age and 9% were women, 14% black, and 43% Latino. The median weight gain at 2 years was 4% (-1.1 – 11.6), “In bivariate analyses, baseline factors significantly associated with massive weight gain included lower CD4 count, higher viral load, and lower baseline BMI.”

In terms of ART itself the therapies were not associated with weight gain. “In this real-world dataset, drug class or specific NRTI use was not associated with massive weight gain which was primarily dependent on baseline CD4 count and HIV viral load.”

The investigators noted there are opportunities for earlier interventions to help with avoiding weight gain. “There was a moderate correlation between early weight gain and massive weight gain at 2 years which can help with patient counseling and interventions aimed at slowing weight gain in this population,” the investigators reported.

The study, “Massive Weight Gain in People with HIV (PWH) Starting Initial Antiretroviral Therapy (ART): Risk Factors and Predictive Ability of Early Weight Gain,” was presented virtually at IDWeek 2021, held September 29-October 3, 2021.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.